Journal of Clinical Oncology, Vol 14, 503-513, Copyright © 1996 by American Society of Clinical Oncology

ARTICLES

Phase II study of topotecan in patients with advanced non-small-cell lung cancer previously untreated with chemotherapy

R Perez-Soler, FV Fossella, BS Glisson, JS Lee, WK Murphy, DM Shin, BL Kemp, JJ Lee, J Kane, RA Robinson, SM Lippman, JM Kurie, MH Huber, MN Raber and WK Hong
Department of Thoracic/Head and Neck Medical Oncology, University of Texas M.D. Anderson Cancer Center, Houston, USA.

PURPOSE: This study was designed to assess the anti-tumor activity of topotecan (TPT) in patients with advanced non-small-cell lung cancer (NSCLC) previously untreated with chemotherapy. PATIENTS AND METHODS: Patients with stage IIIB or IV NSCLC with measurable disease in nonradiated fields were eligible. Other eligibility criteria were Zubrod performance status (PS) < or = 2 and adequate renal and liver function. TPT was administered at a dose of 1.5 mg/m2/d for 5 days over 30 minutes every 21 days. Of 48 registered patients, 40 were fully assessable. Nineteen patients had adenocarcinoma (AD), 14 squamous carcinoma (SCC), and seven poorly differentiated carcinoma. RESULTS: Six patients (15%) achieved a partial remission (PR) (durations: 8, 14, 18, 28, 56, and 61 weeks) and four patients a minor response; 10 patients had stable disease and 20 patients progressive disease. The PR rate was 36% (five of 14 patients) in patients with SCC versus 4% (one of 26 patients) in those with other histologies (P = .014). The overall median survival time was 38 weeks and 30% of patients were alive at 1 year. Grade 3 to 4 granulocytopenia and thrombocytopenia occurred after 76% and 10% of courses administered, respectively. No grade 3 to 4 nonhematologic toxicities were observed. Grade 1 or 2 nonhematologic toxicities consisted of nausea (46% and 5%), vomiting (31% and 7%), and fatigue (53% and 16%). CONCLUSION: TPT at the dose and schedule used has moderate antitumor activity in NSCLC; its activity is mostly limited to patients with SCC. TPT is well tolerated, with myelosuppression of short duration being the most common and limiting toxicity.
CiteULike    Complore    Connotea    Del.icio.us    Digg    Facebook    Reddit    Technorati    Twitter    What's this?

This article has been cited by other articles:

				M. O'Brien, J. Eckardt, and R. Ramlau Recent Advances with Topotecan in the Treatment of Lung Cancer Oncologist, October 1, 2007; 12(10): 1194 - 1204. [Abstract] [Full Text] [PDF]

				R. Ramlau, R. Gervais, M. Krzakowski, J. von Pawel, E. Kaukel, R. P. Abratt, B. Dharan, K. M. Grotzinger, G. Ross, G. Dane, et al. Phase III Study Comparing Oral Topotecan to Intravenous Docetaxel in Patients With Pretreated Advanced Non-Small-Cell Lung Cancer J. Clin. Oncol., June 20, 2006; 24(18): 2800 - 2807. [Abstract] [Full Text] [PDF]

				D. J. Stewart Update on the Role of Topotecan in the Treatment of Non-Small Cell Lung Cancer Oncologist, December 1, 2004; 9(suppl_6): 43 - 52. [Abstract] [Full Text] [PDF]

				M. J. Guarino, C. J. Schneider, S. S. Grubbs, D. D. Biggs, A. L. Himelstein, K. Hogaboom, and S. Tilak A Dose-Escalation Study of Weekly Topotecan, Cisplatin, and Gemcitabine Front-Line Therapy in Patients with Inoperable Non-Small Cell Lung Cancer Oncologist, December 1, 2002; 7(6): 509 - 515. [Abstract] [Full Text] [PDF]

				R. Garcia-Carbonero and J. G. Supko Current Perspectives on the Clinical Experience, Pharmacology, and Continued Development of the Camptothecins Clin. Cancer Res., March 1, 2002; 8(3): 641 - 661. [Abstract] [Full Text] [PDF]

				S. C. White, S. Cheeseman, N. Thatcher, H. Anderson, B. Carrington, S. Hearn, G. Ross, and M. Ranson Phase II Study of Oral Topotecan in Advanced Non-Small Cell Lung Cancer Clin. Cancer Res., March 1, 2000; 6(3): 868 - 873. [Abstract] [Full Text]

				J.-F. Héron Topotecan: An Oncologist's View Oncologist, December 1, 1998; 3(6): 390 - 402. [Abstract] [Full Text]

				S. Winter and M. Weller Potentiation of CD95L-Induced Apoptosis of Human Malignant Glioma Cells by Topotecan Involves Inhibition of RNA Synthesis but Not Changes in CD95 or CD95L Protein Expression J. Pharmacol. Exp. Ther., September 1, 1998; 286(3): 1374 - 1382. [Abstract] [Full Text]

				V. Relias and J. Andrew Skirvin Review : Topoisomerase I inhibitors: 1. Topotecan Journal of Oncology Pharmacy Practice, December 1, 1997; 3(4): 173 - 185. [Abstract] [PDF]